Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
Open Access
- 18 June 2014
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 311 (23), 2406-2413
- https://doi.org/10.1001/jama.2014.5613
Abstract
The tumor necrosis factor α (TNF-α) antagonists infliximab, adalimumab, and certolizumab pegol are highly effective in the treatment of inflammatory bowel disease (IBD), with all 3 agents approved for Crohn disease and infliximab and adalimumab approved for ulcerative colitis.1-6Keywords
This publication has 4 references indexed in Scilit:
- Faculty Opinions recommendation of A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.Published by H1 Connect ,2012
- Faculty Opinions recommendation of Adverse effects of biologics: a network meta-analysis and Cochrane overview.Published by H1 Connect ,2011
- Faculty Opinions recommendation of Infliximab for induction and maintenance therapy for ulcerative colitis.Published by H1 Connect ,2006
- Faculty Opinions recommendation of Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.Published by H1 Connect ,2006